AI-Enabled ECG Management
MyoVista® Insights™ is an AI-enabled ECG Management System that surfaces cardiac dysfunction that standard interpretation misses. Recognized in ACC guidance for AI-ECG screening applications.
What is MyoVista® Insights™?
MyoVista® Insights™ is an AI-enabled ECG Management System that transforms standard 12-lead ECGs into actionable cardiac insights. Using advanced machine learning, it detects conditions often missed by traditional interpretation.
Clinical prioritization - AI-enabled triage to help identify patients who may benefit from further cardiac evaluation
Instant risk stratification - Prioritize patients who need immediate attention with confidence scores
Seamless EHR integration - Results flow directly into Epic with Toolbox designation
Enterprise-Ready Features
Built for healthcare organizations that demand reliability, security, and seamless integration
Vendor Neutral
Works with 12-lead ECG devices from major manufacturers including GE, Philips, Mortara, Cardioline, Welch Allyn, and Baxter.
Cloud Native
Scalable AWS infrastructure designed for reliability. Auto-scaling to handle varying volumes.
AI Marketplace
Deploy multiple algorithms simultaneously. Mix and match AI models for comprehensive analysis.
EHR Integration
Native HL7 FHIR support with Epic Toolbox designation for streamlined integration.
Real-time Processing
Results delivered in under 30 seconds. Immediate actionable insights for clinical workflows.
HIPAA Compliant
Enterprise-grade security with end-to-end encryption for all data.
Integrations & Partners
Works With Your Existing Stack
The Challenge
Standard ECG interpretation cannot detect early-stage cardiac dysfunction, missing conditions that AI pattern recognition can identify.
- Diastolic dysfunction undetectable on standard ECGCirculation, 2022
- Low EF often missed until symptomaticEur Heart J, 2023
- Echo required for definitive diagnosisCost: $500-2,000 per study
HeartSciences Solution
Partner algorithms detect cardiac dysfunction directly from ECG signals, identifying patients who need echocardiography before symptoms appear.
- 87% sensitivity for diastolic dysfunctionJACC: Heart Failure, 2024
- 91% sensitivity for low ejection fractionEur Heart J, 2023
- Works with 12-lead ECG devices from major manufacturersVendor-neutral platform
What Clinicians Say
Healthcare professionals across the country trust HeartSciences for earlier detection and better patient outcomes.
"You've just solved the world's backlog problem"
"You had me at hello, but you really, you REALLY, had me with the comparisons"
"Our GPs love it. They are still salivating over the caliper tool."
"And I loved the filters. This is moving towards my ECG Nirvana!"
"I really like this. What burns me the most is not having complete control of the filters. This prevents 80-year-old patients from being dragged across town to redo the ECG"
"Regarding ECG Overlays. This is awesome. I don't think that anyone else has this feature!"
"There hasn't been a solution in the middle, between the AI-ECG and EHR, that pulls this all together. The problem with the other solutions are that they are all standalone."
Ready to Upgrade Your ECG Workflow?
Schedule a personalized demo and see how MyoVista® Insights™ can improve your practice
Or call us directly: +1-682-244-2578